Drug intelligence / Profile preview

komaniin

Development stage: Preclinical
Modality: Small Molecules

Overview

Komaniin is a novel ellagitannin belonging to the dehydrohexahydroxydiphenoyl (DHHDP) group, isolated from the leaves of *Acer pseudosieboldianum* (Pax) Komarov. It has demonstrated potent chemopreventive and anti-proliferative activities against prostate cancer cells. The compound functions as an epigenetic modulator by inhibiting the activity of DNA methyltransferases, specifically DNMT1, DNMT3a, and DNMT3b. This inhibition leads to the demethylation and subsequent re-expression of the glutathione S-transferase P1 (GSTP1) gene, which is frequently silenced during prostate cancer progression. Research suggests that komaniin and related ellagitannins could serve as promising candidates for the treatment of prostate cancer.

Targets

DNMT1 (DNA (cytosine-5)-methyltransferase 1)DNMT3A (DNA methyltransferase 3 alpha)DNMT3B (DNA (cytosine-5)-methyltransferase 3B)

Beyond the preview

Go deeper on komaniin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on komaniin.

Explore the full profile